Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)

https://www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. *

	Start	2001-01-01 established
	Group	Sanofi (Group) [since May 2011]
	Industry	BIOTECH
	Industry 2	Nanobodies® (Ablynx)
	Person	Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
	Person 2	Heylen, Johan (Ablynx 201411– CCO before GSK + Servier + Wyeth)

	Region	Zwijnaarde
	Country	Belgium
	Street	21 Technologiepark
	City	9052 Zwijnaarde
	Tel	+32-9-262-0000
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	85,187,000 (income, total (2016) 2016-12-31)
	Profit	-1,087,000 (2016-12-31)
	Cash	208,600,000 (2017-09-30)

		* Document for »About Section«:

		Record changed: 2025-03-16